(Q37920918)

25 August 2017

1 reference

title

Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: a review (English)

1 reference

25 August 2017

0 references

Maurizio Coppola

1

1 reference

25 August 2017

Raffaella Mondola

series ordinal

2

1 reference

25 August 2017

publication date

23 August 2011

1 reference

Nordic Journal of Psychiatry

25 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

25 August 2017

volume

66

1 reference

25 August 2017

issue

2

1 reference

25 August 2017

page(s)

73-78

1 reference

Global epidemiology of areca nut usage

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Betel: consumption and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Effects of arecoline on adipogenesis, lipolysis, and glucose uptake of adipocytes-A possible role of betel-quid chewing in metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

A review of betel quid chewing, oral cancer and precancer in Mainland China

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Metabolic effects of the consumption of Areca catechu

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

The inhibition of the conditioned response and the counteraction of schizophrenia by muscarinic stimulation of the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

The effects of an indigenous muscarinic drug, Betel nut (Areca catechu), on the symptoms of schizophrenia: a longitudinal study in Palau, Micronesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Associations between betel nut (Areca catechu) and symptoms of schizophrenia among patients in Nepal: A longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Role of the cholinergic system in the pathology and treatment of schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

The neuropathological effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Re-emergence of striatal cholinergic interneurons in movement disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

The role of acetylcholine in learning and memory

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Increased muscarinic cholinergic receptors in prefrontal cortices of medicated schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Neurotransmitter Receptors in Frontal Cortex of Schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Possible changes in striatal and limbic cholinergic systems in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

High choline concentrations in the caudate nucleus in antipsychotic-naive patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Duration of untreated psychosis vs. N-acetylaspartate and choline in first episode schizophrenia: a 1H magnetic resonance spectroscopy study at 4.0 Tesla

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Side effects of transdermal scopolamine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

The antipsychotic potential of muscarinic allosteric modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Potential role of muscarinic receptors in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Muscarinic receptors as a target for drugs treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Sex differences in drug- and non-drug-induced analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Medicine. What are the right targets for psychopharmacology?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

First- and second-generation antipsychotic medication and cognitive processing in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Treatment of cognitive dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Association of muscarinic m1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Galantamine improves cognition in schizophrenic patients stabilized on risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Schizophrenia and Alzheimer's disease: clinical and pathophysiologic analogies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Central nervous system activity of the proanthocyanidin-rich fraction obtained from Croton celtidifolius in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

Schizophrenia: the fundamental questions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08039488.2011.605172

10.3109/08039488.2011.605172

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference